Anaveon to raise CHF 110 million in Series B Financing. The advisors

Anaveon, a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax. In connection with the Series B financing, Jasper Bos (Forbion), Tim Anderson (Cowen) and Denis Patrick (Pfizer Ventures) will join the Anaveon Board at closing, which is expected before year end.

 

Proceeds from this financing will enable the Anaveon to pursue multiple parallel Phase II programs in order to explore the full therapeutic potential of ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors, and to grow the pipeline into new indications.

 

Vischer advises Anaveon on all legal and tax issues related to the transaction. The Vischer team includes Christian Wyss (partner, corporate/m&a, pictured), Nadia Tarolli (partner, tax), Sebastian Flückiger (senior associate, corporate/m&a), Luzius Zumstein (senior associate, corporate/m&a), Delia FehrBosshard (managing associate, intellectual property) and Christoph Enz (associate, corporate/m&a).

FabioAdmin

SHARE